Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

The present invention relates to certain polyphenol(s) having adjuvant property that can be used for the vaccine preparation. Also, the current invention provides adjuvant system comprising said polyphenol(s) and delivery system such as an immunostimulating reconstituted influenza virosomes (IRIVs). The present invention illustrates the said polyphenol(s) or an adjuvant system comprising of such polyphenol(s) and IRIVs can provide better level of immune response against antigen of interest than conventional vaccine systems. The preferred polyphenol according to the present invention can be beta-sitosterol. Beta-sitosterol can be optionally combined with the known adjuvant(s) to enhance immune response.

The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.

The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.

Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

The present invention is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

The present invention is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

The present invention relates to prime-boost regimens that involve the administration of at least one mRNA construct, such as the use of such constructs in boost administration subsequently to prime administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen. The present invention further describes methods, uses, vaccination compositions, kits and packaged vaccine components related to or useful for one or more of such regimens.

Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

The present invention provides attenuated P. multocida strains that elicit an immune response in animal P. multocida, compositions comprising said strains, methods of vaccination against P. multocida, and kits for use with such methods and compositions. The invention further provides novel, genetically-engineered mutations in P. multocida hyaD and nanPU genes, which are useful in the production of novel attenuated P. multocida bacterial strains.